Pragmatica-Lung is the first of what is likely to be a series of simpler trials with relaxed enrollment criteria and streamlined data collection requirements.
The Pragmatica-Lung trial required many people to start to think differently about conducting phase III clinical trials—and it took a lot of advocacy to make the trial launch quickly, said Ellen Sigal, founder and chair of Friends of Cancer Research.
“There’s nothing like a deadline to make sure you get done what you need to get done.” Joseph A. Califano III, a head and neck surgeon scientist, was named director of Moores Cancer Center at UC San Diego Health, an NCI-designated Comprehensive Cancer Center that serves San Diego County.
Patients with metastatic non-small cell lung cancer who are matched to targeted therapy live longer when liquid biopsies are used to detect genomic alterations in circulating tumor DNA that aren’t picked up by tissue sequencing, according to a study published Nov. 10 in Nature Medicine.
NCI will immediately start the process of streamlining IND-exempt trials in order to make them faster, simpler, more flexible, less expensive, and easier to integrate with clinical practice, James Doroshow, NCI deputy director for clinical and translational research and director of the Division of Cancer Treatment and Diagnosis, said to The Cancer Letter. On Nov. […]
Shortly after Craig Jordan finished his PhD in the 1970s, he was invited by Michael Harper to work at the Worcester Foundation, the “home of the oral contraceptive.”
Pavan Reddy’s motivations to apply for the director’s job at Baylor College of Medicine’s Dan L Duncan Comprehensive Cancer Center included his own research interests.
Catherine Bollard and her team have an ambitious goal: To establish CAR T-cell therapies as the standard of care for pediatric solid tumors within the next 10 years. CAR Ts have made little to no clinical traction in solid tumors thus far, despite their success in some blood cancers.
Researchers at the Gene Editing Institute at ChristianaCare have been moving forward with an effort to use CRISPR-directed gene editing technology in the clinic.
The Bezos family has committed $710.5 million to Fred Hutchinson Cancer Center over the next 10 years—likely the largest single private contribution made to a cancer center in the U.S.
